Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus AMIKIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus AMIKIN.
AMIKACIN SULFATE vs AMIKIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic